-
Mashup Score: 0Factors Considered for Initial Therapy in Myelofibrosis - 3 hour(s) ago
Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases - 7 hour(s) ago
Anne P. O’Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and prognosis.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Initial Impressions and Comparison to Typical Cases - 18 hour(s) ago
Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Cell Therapies Emerge for the Treatment of Acute Myeloid Leukemia - 22 hour(s) ago
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for evolving treatments.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Cellular therapies have emerged as effective treatments for hematologic malignancies, yet progress in applying them to #AML lags behind. However, identifying new targets is driving innovation. @Daver_Leukemia @MusaYilmazMD @MDAndersonNews @StJudeResearch https://t.co/4qm32wr2l8 https://t.co/8ArowVHKCr
-
-
Mashup Score: 1Updates on the iNTEGRATE and ROCKstar Trials - 24 hour(s) ago
Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease, particularly highlighting their ability to inhibit the fibrosis cascade, which offers substantial benefits for patient healing and recovery.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Lessons Learned from REACH-3 Clinical Trial - 2 day(s) ago
Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm compared to 60% in the best-available therapy arm.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Investigating Pregnancy and Transplant Match Issues - 2 day(s) ago
Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Investigating Pregnancy and Transplant Match Issues - 2 day(s) ago
Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
WATCH: Prithviraj Bose, MD, on Factors Considered for Initial Therapy in #Myelofibrosis. #MPNSM | @MDAndersonNews https://t.co/lBeNDZZR0A